A cascade of modules of a network defines cancer progression

被引:22
作者
Thiagalingam, Sam
机构
[1] Boston Univ, Sch Med, Genet Program, Dept Med, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Canc Res Ctr, Dept Genet & Genom, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA
关键词
D O I
10.1158/0008-5472.CAN-06-0993
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Similar histologic subtypes of cancers often exhibit different spectrum of genetic and epigenetic alterations. The heterogeneity observed due to lack of consistent and defined alterations affecting a unique set of gene(s) or gene products in cancers derived from a specific tissue, or an organ, pose a challenge in unraveling the molecular basis of the disease. This dilemma also complicates diagnosis, prognosis, effective management, and treatment modalities. To streamline the available and emerging data into a coherent scheme of events, a multimodular molecular network (MMMN) cancer progression model is presented as a roadmap to dissect the complexity inherent to this disease. The fact that disruption/dysregulation of more than one alternate target gene could affect the functionality of each specific module of a cascade provides a molecular basis for genetic and epigenetic heterogeneity in any given cancer. Polymorphisms/mutations as well as the extracellular matrix and or the epigenetically/genetically conditioned surrounding stromal cells could also influence the rate of turnorigenesis and the properties of the tumor cells. The formulation of MMMN cancer progression models for specific cancers is likely to provide the blueprints for the markers and targets to aid diagnosis, prevention, and therapy of this deadly disease.
引用
收藏
页码:7379 / 7385
页数:7
相关论文
共 46 条
[21]   Cancer-susceptibility genes - Gatekeepers and caretakers [J].
Kinzler, KW ;
Vogelstein, B .
NATURE, 1997, 386 (6627) :761-&
[22]   Tumor suppressor genes in normal and malignant hematopoiesis [J].
Krug, U ;
Ganser, A ;
Koeffler, HP .
ONCOGENE, 2002, 21 (21) :3475-3495
[23]   Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients [J].
Liu, B ;
Parsons, R ;
Papadopoulos, N ;
Nicolaides, NC ;
Lynch, HT ;
Watson, P ;
Jass, JR ;
Dunlop, M ;
Wyllie, A ;
Peltomaki, P ;
delaChapelle, A ;
Hamilton, SR ;
Vogelstein, B ;
Kinzler, KW .
NATURE MEDICINE, 1996, 2 (02) :169-174
[24]  
Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO
[25]  
2-P
[26]   Integration of Smad and MAPK pathways:: a link and a linker revisited [J].
Massagué, J .
GENES & DEVELOPMENT, 2003, 17 (24) :2993-2997
[27]   RETRACTED: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells (Retracted article. See vol. 126, pg. 1603, 2016) [J].
Melillo, RM ;
Castellone, MD ;
Guarino, V ;
De Falco, V ;
Cirafici, AM ;
Salvatore, G ;
Caiazzo, F ;
Basolo, F ;
Giannini, R ;
Kruhoffer, M ;
Orntoft, T ;
Fusco, A ;
Santoro, M .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (04) :1068-1081
[28]  
Méniel V, 2005, CANCER RES, V65, P410
[29]   WNT and β-catenin signalling:: Diseases and therapies [J].
Moon, RT ;
Kohn, AD ;
De Ferrari, GV ;
Kaykas, A .
NATURE REVIEWS GENETICS, 2004, 5 (09) :689-699
[30]   Breast cancer genetics: What we know and what we need [J].
Nathanson, KN ;
Wooster, R ;
Weber, BL .
NATURE MEDICINE, 2001, 7 (05) :552-556